Loss of Ecrg4 improves calcium oxalate nephropathy.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2022
accepted:
27
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Kidney stone is one of the most frequent urinary tract diseases, affecting 10% of the population and displaying a high recurrence rate. Kidney stones are the result of salt supersaturation, including calcium and oxalate. We have previously identified Esophageal cancer-related gene 4 (Ecrg4) as being modulated by hypercalciuria. Ecrg4 was initially described as a tumor suppressor gene in the esophagus. Lately, it was shown to be involved as well in apoptosis, cell senescence, cell migration, inflammation and cell responsiveness to chemotherapy. To the best of our knowledge, nothing is known about ECRG4's function in the renal tissue and its relationship with calciuria. We hypothesized that the increased expression of Ecrg4 mRNA is triggered by hypercalciuria and might modulate intratubular calcium-oxalate precipitation. In this study, we have first (i) validated the increased Ecrg4 mRNA in several types of hypercalciuric mouse models, then (ii) described the Ecrg4 mRNA expression along the nephron and (iii) assessed ECRG4's putative role in calcium oxalate nephropathy. For this, Ecrg4 KO mice were challenged with a kidney stone-inducing diet, rich in calcium and oxalate precursor. Taken together, our study demonstrates that Ecrg4's expression is restricted mainly to the distal part of the nephron and that the Ecrg4 KO mice develop less signs of tubular obstruction and less calcium-oxalate deposits. This promotes Ecrg4 as a modulator of renal crystallization and may open the way to new therapeutic possibilities against calcium oxalate nephropathy.
Identifiants
pubmed: 36227903
doi: 10.1371/journal.pone.0275972
pii: PONE-D-22-06861
pmc: PMC9560046
doi:
Substances chimiques
Calcium, Dietary
0
RNA, Messenger
0
Calcium Oxalate
2612HC57YE
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275972Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell Mol Life Sci. 2019 Dec;76(24):5027-5039
pubmed: 31190084
Sci Rep. 2018 Mar 6;8(1):4048
pubmed: 29511297
Clin Chem Lab Med. 2005;43(6):590-600
pubmed: 16006254
Front Genet. 2020 Aug 14;11:846
pubmed: 32922434
J Urol. 2001 Sep;166(3):1078-82
pubmed: 11490302
J Am Soc Nephrol. 2021 Mar 4;:
pubmed: 33769948
Physiol Rep. 2020 Apr;8(7):e14410
pubmed: 32291966
BMC Cancer. 2009 Dec 17;9:447
pubmed: 20017917
PLoS One. 2011;6(11):e27656
pubmed: 22110708
J Am Soc Nephrol. 2005 Apr;16(4):878-91
pubmed: 15743993
J Clin Invest. 2020 Apr 1;130(4):1948-1960
pubmed: 32149733
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
Int J Cancer. 2009 Oct 1;125(7):1505-13
pubmed: 19521989
J Urol. 2007 Mar;177(3):979-82
pubmed: 17296391
Nucleic Acids Res. 2018 Jan 4;46(D1):D1271-D1281
pubmed: 29106664
Front Med. 2019 Oct;13(5):540-546
pubmed: 30003403
Am J Physiol Regul Integr Comp Physiol. 2015 Jul 1;309(1):R85-92
pubmed: 25947170
Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1337-50
pubmed: 27009338
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
J Am Soc Nephrol. 1999 Nov;10 Suppl 14:S376-80
pubmed: 10541267
J Urol. 2010 Sep;184(3):1189-96
pubmed: 20663521
World J Gastroenterol. 2003 Jun;9(6):1174-8
pubmed: 12800218
Sci Rep. 2018 Nov 5;8(1):16319
pubmed: 30397242
Nephron. 1999;81 Suppl 1:8-17
pubmed: 9873209